Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Accumulated Depreciation (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Accumulated Depreciation for 9 consecutive years, with $49.7 million as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Depreciation rose 24.66% to $49.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was $49.7 million, a 24.66% increase, with the full-year FY2024 number at $49.7 million, up 24.66% from a year prior.
  • Accumulated Depreciation was $49.7 million for Q4 2024 at Intellia Therapeutics, up from $39.9 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $49.7 million in Q4 2024 to a low of $19.3 million in Q4 2020.
  • A 5-year average of $33.6 million and a median of $33.2 million in 2022 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: skyrocketed 35.09% in 2021, then rose 20.07% in 2023.
  • Intellia Therapeutics' Accumulated Depreciation stood at $19.3 million in 2020, then surged by 35.09% to $26.1 million in 2021, then rose by 27.13% to $33.2 million in 2022, then rose by 20.07% to $39.9 million in 2023, then rose by 24.66% to $49.7 million in 2024.
  • Per Business Quant, the three most recent readings for NTLA's Accumulated Depreciation are $49.7 million (Q4 2024), $39.9 million (Q4 2023), and $33.2 million (Q4 2022).